Amgen's PCSK9 Inhibitor Gets FDA Nod For Stroke Prevention
Zacks Investment Research | Dec 03, 2017 08:10PM ET
Amgen, Inc. (NASDAQ:AMGN) announced that the FDA has approved its regulatory application seeking approval to include data from the cardiovascular outcomes study, FOURIER, on the label of its PCSK9 inhibitor, Repatha.
With the label expansion, Repatha can now be prescribed to prevent heart attacks, strokes and coronary revascularizations in patients with established cardiovascular disease.
This year so far, Amgen’s shares are up 21.2%, better than 2.6% increase registered by the .
A better-ranked large-cap pharma stock is Johnson & Johnson (NYSE:JNJ) , which has a Zacks Rank #2 (Buy).
Shares of J&J have risen 21.5% this year so far while 2018 earnings estimates have gone up 0.7% in the past 60 days.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.